Zhitong Finance App News, Sinopharm Hyundai (600420.SH) announced that the company expects to achieve net profit attributable to shareholders of listed companies of 245 million yuan to 305 million yuan from January to June 2026, a year-on-year decrease of 63.54% to 54.61%.

Currently, the field of antibiotic intermediates and APIs is experiencing multiple challenges. On the one hand, it is influenced by international geopolitics and protectionism is rising in overseas markets; on the other hand, excessive domestic antibiotic production capacity and collection effects are transmitted upstream of the industrial chain, and the operating pressure on the industry has increased significantly. Faced with adverse factors, the company optimized its sales structure and maintained a competitive advantage in exchange for price in exchange for volume. As the prices of some key products dropped significantly compared to the same period last year, profit margins were severely compressed, and the gross margin of the company's pharmaceutical intermediates and APIs fell to 17.32% from 32.04% in the same period last year, resulting in the company's net profit level attributable to shareholders of listed companies falling by more than 50% in the current period compared to the same period last year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.